# Rocklatan® Evaluation

> **NCT05283395** · PHASE4 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 136 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution

## Key facts

- **NCT ID:** NCT05283395
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-28
- **Primary completion:** 2023-03-22
- **Final completion:** 2023-03-22
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05283395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05283395, "Rocklatan® Evaluation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05283395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*